These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 9138599

  • 1. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells.
    Silvestrini R, Gornati D, Zaffaroni N, Bearzatto A, De Marco C.
    Breast Cancer Res Treat; 1997 Jan; 42(2):103-12. PubMed ID: 9138599
    [Abstract] [Full Text] [Related]

  • 2. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
    Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L, Epirubicin-Lonidamine Group, Orbassano, Torino, Italy.
    J Clin Oncol; 2002 Oct 15; 20(20):4150-9. PubMed ID: 12377958
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
    Gebbia V, Borsellino N, Testa A, Latteri MA, Milia V, Valdesi M, Giotta F, Gebbia N, Colucci G.
    Anticancer Drugs; 1997 Nov 15; 8(10):943-8. PubMed ID: 9436637
    [Abstract] [Full Text] [Related]

  • 4. In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells.
    Villa R, Zaffaroni N, Orlandi L, Bearzatto A, Costa A, Silvestrini R.
    Eur J Cancer; 1994 Nov 15; 30A(10):1534-40. PubMed ID: 7833114
    [Abstract] [Full Text] [Related]

  • 5. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
    Dogliotti L, Berruti A, Buniva T, Zola P, Baù MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M, Perroni D.
    J Clin Oncol; 1996 Apr 15; 14(4):1165-72. PubMed ID: 8648371
    [Abstract] [Full Text] [Related]

  • 6. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
    De Lena M, Lorusso V, Bottalico C, Brandi M, De Mitrio A, Catino A, Guida M, Latorre A, Leone B, Vallejo C, Gargano G.
    J Clin Oncol; 1997 Oct 15; 15(10):3208-13. PubMed ID: 9336357
    [Abstract] [Full Text] [Related]

  • 7. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
    Ianniello GP, De Cataldis G, Comella P, Scarpati MD, Maiorino A, Brancaccio L, Cioffi R, Lombardi A, Carnicelli P, Tinessa V.
    Cancer; 1996 Jul 01; 78(1):63-9. PubMed ID: 8646728
    [Abstract] [Full Text] [Related]

  • 8. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells.
    Villa R, Orlandi L, Berruti A, Dogliotti L, Zaffaroni N.
    Int J Oncol; 1999 Jan 01; 14(1):133-8. PubMed ID: 9863019
    [Abstract] [Full Text] [Related]

  • 9. Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis.
    Orlandi L, Zaffaroni N, Bearzatto A, Villa R, De Marco C, Silvestrini R.
    Int J Cancer; 1998 Oct 29; 78(3):377-84. PubMed ID: 9766575
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
    Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A.
    Int J Cancer; 1992 Nov 11; 52(5):813-7. PubMed ID: 1428236
    [Abstract] [Full Text] [Related]

  • 11. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
    Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei E.
    Cancer Chemother Pharmacol; 1989 Nov 11; 25(1):32-6. PubMed ID: 2590999
    [Abstract] [Full Text] [Related]

  • 12. Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
    Lopez M, Vici P, Di Lauro L, Paoletti G, Gionfra T, Conti F, Carpano S, Pignatti F, Giannarelli D.
    Eur J Cancer; 1995 Sep 11; 31A(10):1611-4. PubMed ID: 7488410
    [Abstract] [Full Text] [Related]

  • 13. Schedule-dependent modulation of idarubicin cytotoxicity by lonidamine in human lymphoma cell lines.
    Zaffaroni N, Villa R, Gornati D, Folini M, Silvestrini R.
    Int J Oncol; 1997 Oct 11; 11(4):675-9. PubMed ID: 21528260
    [Abstract] [Full Text] [Related]

  • 14. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
    Pacini P, Rinaldini M, Algeri R, Guarneri A, Tucci E, Barsanti G, Neri B, Bastiani P, Marzano S, Fallai C.
    Eur J Cancer; 2000 May 11; 36(8):966-75. PubMed ID: 10885599
    [Abstract] [Full Text] [Related]

  • 15. Weekly epirubicin plus lonidamine in advanced breast carcinoma.
    Nisticò C, Garufi C, Milella M, D'Ottavio AM, Vaccaro A, Fabi A, Terzoli E.
    Breast Cancer Res Treat; 1999 Aug 11; 56(3):233-7. PubMed ID: 10573114
    [Abstract] [Full Text] [Related]

  • 16. Potentiation of antiproliferative drug activity by lonidamine in hepatocellular carcinoma cells.
    Ricotti L, Tesei A, De Paola F, Milandri C, Amadori D, Frassineti GL, Ulivi P, Zoli W.
    J Chemother; 2003 Oct 11; 15(5):480-7. PubMed ID: 14598941
    [Abstract] [Full Text] [Related]

  • 17. In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.
    Savini S, Zoli W, Nanni O, Volpi A, Frassineti GL, Magni E, Flamigni A, Amadori A, Amadori D.
    Breast Cancer Res Treat; 1992 Oct 11; 24(1):27-34. PubMed ID: 1463869
    [Abstract] [Full Text] [Related]

  • 18. In vitro potentiation by lonidamine of the sc-RIP saporin 6 effect in a human metastatic breast cancer cell line.
    Roncuzzi L, Zoli W, Bajorko P, Gasperi-Campani A.
    Anticancer Res; 1995 Oct 11; 15(3):773-6. PubMed ID: 7645957
    [Abstract] [Full Text] [Related]

  • 19. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu SD, Frei E.
    Cancer Res; 1991 Feb 01; 51(3):780-4. PubMed ID: 1988117
    [Abstract] [Full Text] [Related]

  • 20. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
    Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, Lepidini G, Vici P, Barone C, Ferretti G, Di Cosimo S, Nistico C, Carlini P, Conti F, Di Lauro L, Botti C, Vitucci C, Fabi A, Giannarelli D, Marolla P.
    J Clin Oncol; 2003 Sep 15; 21(18):3462-8. PubMed ID: 12972521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.